BR112013020510A2 - inibidores de catepsina c - Google Patents

inibidores de catepsina c

Info

Publication number
BR112013020510A2
BR112013020510A2 BR112013020510A BR112013020510A BR112013020510A2 BR 112013020510 A2 BR112013020510 A2 BR 112013020510A2 BR 112013020510 A BR112013020510 A BR 112013020510A BR 112013020510 A BR112013020510 A BR 112013020510A BR 112013020510 A2 BR112013020510 A2 BR 112013020510A2
Authority
BR
Brazil
Prior art keywords
cathepsin
inhibitors
butenamides
amino
formula
Prior art date
Application number
BR112013020510A
Other languages
English (en)
Inventor
Christopher E Neipp
Michael R Palovich
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46638952&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112013020510(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of BR112013020510A2 publication Critical patent/BR112013020510A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

inibidores de catepsina c são aqui reveladas 4-amino-2-butenamidas de fórmula (i) com atividade farmacológica, composições farmacêuticas contendo as mesmas e métodos para o tratamento de doenças mediadas pela enzima catepsina c, por exemplo, a doença pulmonar obstrutiva crônica.
BR112013020510A 2011-02-11 2012-02-09 inibidores de catepsina c BR112013020510A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161441840P 2011-02-11 2011-02-11
PCT/US2012/024428 WO2012109415A1 (en) 2011-02-11 2012-02-09 Cathepsin c inhibitors

Publications (1)

Publication Number Publication Date
BR112013020510A2 true BR112013020510A2 (pt) 2016-07-12

Family

ID=46638952

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013020510A BR112013020510A2 (pt) 2011-02-11 2012-02-09 inibidores de catepsina c

Country Status (23)

Country Link
US (2) US8841463B2 (pt)
EP (1) EP2672821B9 (pt)
JP (1) JP5931929B2 (pt)
KR (1) KR20140048857A (pt)
CN (1) CN103491777B (pt)
AR (1) AR085163A1 (pt)
AU (1) AU2012214405B2 (pt)
BR (1) BR112013020510A2 (pt)
CA (1) CA2827157A1 (pt)
CL (1) CL2013002325A1 (pt)
CO (1) CO6741219A2 (pt)
DO (1) DOP2013000182A (pt)
EA (1) EA023168B1 (pt)
ES (1) ES2583091T3 (pt)
IL (1) IL227814A0 (pt)
MA (1) MA34961B1 (pt)
MX (1) MX2013009279A (pt)
PE (1) PE20140999A1 (pt)
SG (1) SG192669A1 (pt)
TW (1) TW201302736A (pt)
UY (1) UY33905A (pt)
WO (1) WO2012109415A1 (pt)
ZA (1) ZA201306074B (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014091443A1 (en) 2012-12-13 2014-06-19 Glaxo Group Limited Cathepsin c inhibitors for treating cystic fibrosis, non-cystic fibrosis bronchiectasis, and anca-associated vasculitis
NO2699580T3 (pt) 2014-01-24 2018-02-24

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2622581B1 (fr) * 1987-11-03 1990-02-16 Inorgan Sa Rech Develop Pharm Nouveaux derives de l-proline, leur preparation et leurs applications biologiques
US6232299B1 (en) 1996-05-01 2001-05-15 Eli Lilly And Company Use of protein kinase C inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy
CN1240355A (zh) * 1996-05-01 2000-01-05 伊莱利利公司 蛋白激酶c抑制剂增强溶癌剂和放射治疗的临床功效的用途
US6214799B1 (en) 1996-05-14 2001-04-10 Agouron Pharmaceuticals, Inc. Antipicornaviral compounds and methods for their use and preparation
WO2002048097A1 (en) 2000-12-12 2002-06-20 Corvas International, Inc. Compounds, compositions and methods for treatment of parasitic infections
CN101675052A (zh) * 2007-04-12 2010-03-17 辉瑞大药厂 作为蛋白酶c抑制剂的3-酰氨基-吡咯并[3,4-c]吡唑-5(1h,4h,6h)甲醛衍生物
CN102574830A (zh) * 2009-05-07 2012-07-11 阿斯利康(瑞典)有限公司 取代的1-氰基乙基杂环基甲酰胺化合物750
UY32827A (es) * 2009-08-12 2011-02-28 Glaxo Group Ltd Inhibidores de catepsina c
WO2012119941A1 (en) 2011-03-04 2012-09-13 Prozymex A/S Peptidyl nitrilcompounds as peptidase inhibitors

Also Published As

Publication number Publication date
KR20140048857A (ko) 2014-04-24
PE20140999A1 (es) 2014-09-11
CO6741219A2 (es) 2013-08-30
US20130324584A1 (en) 2013-12-05
EP2672821A1 (en) 2013-12-18
US20140364476A1 (en) 2014-12-11
UY33905A (es) 2012-08-31
SG192669A1 (en) 2013-09-30
CN103491777A (zh) 2014-01-01
CN103491777B (zh) 2015-05-06
MX2013009279A (es) 2013-10-28
DOP2013000182A (es) 2014-03-16
ZA201306074B (en) 2014-04-30
EP2672821B1 (en) 2016-04-20
AR085163A1 (es) 2013-09-11
EA023168B1 (ru) 2016-04-29
AU2012214405A1 (en) 2013-04-18
CA2827157A1 (en) 2012-08-16
US8841463B2 (en) 2014-09-23
JP2014506577A (ja) 2014-03-17
EP2672821A4 (en) 2014-08-06
ES2583091T3 (es) 2016-09-19
NZ614540A (en) 2015-03-27
CL2013002325A1 (es) 2014-01-03
US9187461B2 (en) 2015-11-17
IL227814A0 (en) 2013-09-30
EP2672821B9 (en) 2016-11-23
MA34961B1 (fr) 2014-03-01
JP5931929B2 (ja) 2016-06-08
EA201391155A1 (ru) 2014-01-30
WO2012109415A1 (en) 2012-08-16
AU2012214405B2 (en) 2015-07-23
TW201302736A (zh) 2013-01-16

Similar Documents

Publication Publication Date Title
MY165087A (en) Neprilysin inhibitors
BR112014002202A2 (pt) macrociclos como inibidores de fator xia
CO6551666A2 (es) Macrociclos como inhibidores del factor de coagulacion (fxia)
BR112014012129A8 (pt) inibidores heterocíclicos de glutaminase
PH12015500260A1 (en) Neprilysin inhibitors
MX342212B (es) Inhibidores de neprilisina.
GEP20156347B (en) Benzodioxane inhibitors of leukotriene production
MX2013006802A (es) Inhibidores de neprilisina.
MY170935A (en) Neprilysin inhibitors
MX2014004766A (es) Inhibidores de arginasa y sus aplicaciones terapeuticas.
BR112013001753A2 (pt) método para preparar uma composição d einter-alfa-inibidor (iaip) eriquecida de plasma, solução aquosa de iaip, e, método para tratar uma doença ou distúrbio associado com disfunção de iaip e associado com atividadede protease de serina no plasma aumentada.
PH12016501462A1 (en) Neprilysin inhibitors
GEP20186885B (en) Novel compounds
CY1116775T1 (el) Παραγωγα πυριμιδονης ως αναστολεις της ιστικης τρανσγλουταμινασης
BR112013030264A2 (pt) ácidos acéticos de benzociclohepteno
MA32183B1 (fr) Pyrimidylcyclopentanes hydroxylés utilisés comme inhibiteurs de protéine kinase akt
BR112012015677A2 (pt) Compostos farmacêuticos.
BR112017000584A2 (pt) inibidores da aldosterona sintase
BR112013027395A2 (pt) inibidores de 17alfa-hidroxilase/c17,20-liase
BR112013020510A2 (pt) inibidores de catepsina c
CO6612187A2 (es) Inhibidores de catepsina c
CR20130522A (es) Inhibidores de la péptido desformilasa
EA201591125A1 (ru) Производные пиридона и их применение для лечения туберкулеза
CR20120103A (es) Inhibidores de catepsina c
BR112017005859A2 (pt) inibidores de aldosterona sintase

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2500 DE 04-12-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.